The group's principal activity is to develop innovative products to improve quality of life disorders in men and women, with a focus on sexual dysfunction. The group develops and markets muse (medicated urethral system for erection) and actis, two innovations used for the treatment of men with erectile dysfunction (impotence). Currently, the group focuses on the development of the following products: alista, for the treatment of female sexual arousal disorder; ta-1790, for the treatment of male erectile dysfunction; and vi-0162 and vi-0134, for the treatment of premature ejaculation. The group markets and distributes its products in domestic and international markets.
